U.S. markets closed
  • S&P Futures

    3,730.25
    -1.75 (-0.05%)
     
  • Dow Futures

    29,739.00
    -11.00 (-0.04%)
     
  • Nasdaq Futures

    11,541.50
    -14.25 (-0.12%)
     
  • Russell 2000 Futures

    1,721.00
    +0.20 (+0.01%)
     
  • Crude Oil

    82.28
    +0.13 (+0.16%)
     
  • Gold

    1,664.60
    -5.40 (-0.32%)
     
  • Silver

    18.82
    -0.06 (-0.32%)
     
  • EUR/USD

    0.9687
    -0.0052 (-0.53%)
     
  • 10-Yr Bond

    3.7050
    -0.2590 (-6.53%)
     
  • Vix

    30.18
    -2.42 (-7.42%)
     
  • GBP/USD

    1.0805
    -0.0081 (-0.74%)
     
  • USD/JPY

    144.2500
    +0.1280 (+0.09%)
     
  • BTC-USD

    19,560.65
    +582.16 (+3.07%)
     
  • CMC Crypto 200

    447.32
    +18.54 (+4.32%)
     
  • FTSE 100

    7,005.39
    +20.80 (+0.30%)
     
  • Nikkei 225

    26,409.74
    +235.76 (+0.90%)
     

Neurological Disorder Drugs Market to Reach Tremendous Value of US$ 125.60 Billion during Forecast 2022-2029, Size, Share, Industry Growth, Competitive Analysis and Trends forecast

·14 min read
Data Bridge Market Research
Data Bridge Market Research

The market’s growth is propelled by an increase in the geriatric population, which leads to the presentation of numerous neurological problems. Cerebrovascular disorders such as stroke and migraine affect people of all ages in countries including Germany, the United Kingdom, and Italy.

NEW YORK, Sept. 19, 2022 (GLOBE NEWSWIRE) -- A Qualitative Research Study accomplished by Data Bridge Market research's database of 350 pages, titled as “Global Neurological Disorder Drugs Market” with 100+ market data Tables, Pie Charts, Graphs & Figures spread through Pages and easy-to-understand detailed analysis. Neurological Disorder Drugs market report is a wide-ranging background analysis of the Healthcare industry, which includes an assessment of the parental market. The business report is a professional and detailed market study focusing on primary and secondary drivers, market share, leading segments, and geographical analysis. The report also aids in prioritizing market goals and attaining profitable business. This industry analysis report has an examination of various features that are relied upon to witness the quickest development amid the estimated forecast frame. Neurological Disorder Drugs marketing report consists of the most recent market information with which companies can attain an in-depth analysis of the Healthcare industry and future trends.

Data Bridge Market Research analyses that the neurological disorder drugs market was valued at USD 79.40 billion in 2021 and is expected to reach USD 125.60 billion by 2029, registering a CAGR of 5.9% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Get Access to Sample Report (Including Graphs, Charts & Figures) @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-neurological-disorder-drugs-market

Market Overview:-

A neurological disease occurs when any portion of the brain or nervous system malfunctions, causing physical and/or psychological symptoms. Neurological disorders are treated with a variety of medications, including antipsychotics, antiepileptics, anticholinergics, and analgesics. Furthermore, the drug that is prescribed is primarily determined by the patient's neurological condition. These medications aid in the management of neurological conditions, symptom reduction, and improved quality of life. Corticosteroids, which are widely used to treat multiple sclerosis and help reduce inflammation, are among the most commonly used neurological medications.

Globally, neurological disorders are the main cause of death. It is defined as both central and peripheral nervous system disorders. The diseases primarily affect the elderly population. It may progress and necessitate long-term treatment. Congenital neurological abnormalities appear during the early stages of embryo development and can be detected at birth. A variety of factors, such as traumatic brain injuries, immunological problems, postnatal injections, spinal cord injuries, neoplasia, and exposure to ambient chemicals or poisons, can cause acquired neurological disorders after birth. Many bacterial, viral, fungal, and parasite diseases can damage the nervous system, resulting in neurological illnesses.

Leading Key Players Operating in the Neurological Disorder Drugs Market Includes:-

  • Merck KGaA (Germany)

  • Eisai Co., Ltd. (Japan)

  • AstraZeneca (U.K.)

  • Sanofi (France)

  • Novartis AG (Switzerland)

  • Abbott (U.S.)

  • F. Hoffmann-La Roche Ltd. (Switzerland)

  • Teva Pharmaceutical Industries Ltd. (Ireland)

  • Pfizer Inc. (U.S.)

  • GlaxoSmithKline plc (U.K.)

Market research analysis covered in the top-notch Neurological Disorder Drugs market survey report aids the management of a firm in planning by providing accurate and up-to-date information about the consumer’s demands, their changing tastes, attitudes, preferences, and buying intentions etc. It endows with all the guidelines about planning of advertising and sales promotion efforts. This international market report also includes a comprehensive evaluation of the market’s growth prospects and restrictions. With the data and insights covered in this business report, marketing of goods can be made efficient and economical which leads to elimination of all type of wastage. Neurological Disorder Drugs market document is an indispensable model to have increments in business activities, qualitative work done and enhanced profits.

Recent Development

  • In September 2021, Sumitomo Dainippon Pharma and Otsuka had announced a collaboration as well as license agreement for four psychiatry and neurology compounds namely ulotaront (SEP-363856), SEP-4199, SEP-378614, and SEP-380135. Under the terms of the partnership, Sunovion and Otsuka will split the costs and revenues of clinical trials, regulatory applications, and commercialization in each of these nations and areas. Additional ulotaront indications, and also SEP-378614 and SEP-380135 indications, will be identified after future Sumitomo Dainippon Pharma Group and Otsuka consultations.

Get Detailed 350 Pages Report to Understand More @ https://www.databridgemarketresearch.com/checkout/buy/enterprise/global-neurological-disorder-drugs-market

Opportunities

  • Development of new drugs

Moreover, the market's growth is fueled by an increase in the development of new drugs. This will provide beneficial opportunities for the market growth. Brain injuries and neurological disorders are among the major causes of death around the world. As a result, researchers are pursuing chances to produce new medications that could improve the treatment of neurological disorders by altering glucose metabolism. For instance, Gero Discovery, a provider of novel therapeutic alternatives for neurodegenerative disorders, recently revealed the discovery of a prospective medicine that uses the technique of glucose metabolism alteration in stressed neurons to assist avoid neuronal death. To create novel treatments, companies in the neurological disorder drugs industry need work with qualified researchers.

  • Increase in the number of research and development activities       

The increase in the number of research and development activities is estimated to provide various beneficial opportunities for the neurological disorder drugs market’s growth. New therapeutic techniques for the treatment of Parkinson's disease are being adopted by companies in the neurological disorder pharmaceuticals market. This leads to high number of research activities to better understand the disease's genetic risk factors in order to find better drugs. As a result, mutations in the GBA1 gene are emerging as a prospective therapeutic development strategy. Mutations in the gene, however, may cause GCase (glucocerebrosidase) enzyme deficiencies. As a result, manufacturers in the neurological disorder pharmaceuticals market are concentrating on activating wild type GCase in order to produce new therapeutic molecules for the treatment of Parkinson's disease.

Moreover, the market's growth is fueled by rising investment for the development of advanced technologies and increase in the number of emerging markets. These factors will provide beneficial opportunities for the neurological disorder drugs market growth

How will this Market Intelligence Report Benefit You?

  • The report offers statistical data in terms of value (US$) as well as Volume (units)

  • Exclusive insight into the key trends affecting this industry, although key threats, opportunities and disruptive technologies that could shape the Global Market supply and demand

  • The report tracks the leading market players that will shape and impact this Market most

  • The data analysis present in this report is based on the combination of both primary and secondary resources

  • The report helps you to understand the real effects of key market drivers or retainers on this business

Market Scope and Market Size:-

Indication

  • Epilepsy

  • Alzheimer’s Disease

  • Parkinson’s Disease

  • Multiple Sclerosis

  • Cerebrovascular Disease

Drug Class

  • Cholinesterase Inhibitors

  • NMDA Receptor Antagonists

  • Antiepileptic

  • Antipsychotic and Antidepressant

Route of Administration

  • Oral

  • Parenteral

End-Users

  • Hospitals

  • Specialty Clinics

  • Homecare

Distribution Channel

  • Hospital Pharmacy

  • Retail Pharmacy

  • Online Pharmacy

Get Latest Edition of Market Study Now @ https://www.databridgemarketresearch.com/reports/global-neurological-disorder-drugs-market

Neurological Disorder Drugs Market, By Region:

Global Neurological Disorder Drugs market is analyzed and market size insights and trends are provided by country, product as referenced above.

The countries covered in the Neurological Disorder Drugs market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the Neurological Disorder Drugs market because of the rise in the cases of arrhythmic diseases, favorable reimbursement policies for patients, high demand for advanced treatment methods and developed healthcare infrastructure in the region. Asia-Pacific is estimated to grow in the forecast period due to the high prevalence of cardiovascular diseases, increase in adoption of advanced digital devices, large population and launch of new innovative products.

Neurological Disorder Drugs Market Dynamics:

Drivers:

  • Growing geriatric population:

The market’s growth is propelled by an increase in the geriatric population, which leads to the presentation of numerous neurological problems. Cerebrovascular disorders such as stroke and migraine affect people of all ages in countries including Germany, the United Kingdom, and Italy. In adults aged 45 to 84, France, Sweden, Greece, Denmark, and Russia have high rates of cerebrovascular illness. As per a study published in the NCBI in 2018, the prevalence of stroke in Singapore was 7.67 percent among persons aged 65 and up.

  • Increasing investment for healthcare infrastructure:

Another significant factor influencing the growth rate of dermatitis market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

  • Rising awareness about early disease diagnosis:

The neurological disorder drugs market is expected to grow due to rising awareness associated with early disease diagnosis through awareness campaigns by government regulatory bodies and private organizations, and market entry of efficient drugs in the near future, owing to the presence of a strong drug pipeline. As per a report published by the Pharmaceutical Research and Manufacturers of America (PhRMA) in April 2018, biopharmaceutical companies in the United States are currently developing 537 medications for various neurological illnesses. 95 drugs for brain tumors, 46 for chronic pain, and 92 for Alzheimer's disease are among them. Multiple sclerosis, migraines, amyotrophic lateral sclerosis, and Parkinson's disease are among the 30 illnesses being researched.

Furthermore, surging number of government initiatives to spread awareness and increasing prevalence of neurological diseases such as dementia will result in the expansion of neurological disorder drugs market. Along with this, sedentary lifestyle of people and will enhance the growth rate of the market.

TABLE OF CONTENTS

Part 01: Executive Summary

Part 02: Scope Of The Report

Part 03: Research Methodology

Part 04: Market Landscape

Part 05: Pipeline Analysis

Part 06: Market Sizing

Part 07: Five Forces Analysis

Part 08: Market Segmentation

Part 09: Customer Landscape

Part 10: Regional Landscape

Part 11: Decision Framework

Part 12: Drivers And Challenges

Part 13: Market Trends

Part 14: Vendor Landscape

Part 15: Vendor Analysis

Part 16: Appendix

Check Complete Table of Contents @ https://www.databridgemarketresearch.com/toc/?dbmr=global-neurological-disorder-drugs-market

Browse More Reports:-

  • Risuteganib in Neurological Disorder Treatment Market, By Type (Angiostatic proteins, Anti-inflammatories, Carboxylic Acids, Eye Disorder Therapies, Neuroprotectants, Oligopeptides, Pyrrolidines, Small Molecules), Application (Dry age-related macular degeneration, Retinal disorders, Wet age-related macular degeneration, Neurological Disorder,  Others), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) https://www.databridgemarketresearch.com/reports/global-risuteganib-in-neurological-disorder-treatment-market

  • Neurological Biomarkers Market, By Product Type (Genomics Biomarker, Proteomics Biomarker, Imaging Biomarker, Metabolomics Biomarker, Others), Indication (Spinal Muscular Atrophy, Parkinson’s Disease, Schizophrenia, Huntington’s Disease, Alzheimer’s Disease, Depression, Multiple Sclerosis), Imaging Techniques (Transcranial Magnetic Stimulation, Diffusion Tensor Imaging, Conventional Structural MRI, Functional Magnetic Resonance Imaging, Positron Emission Tomography), Services (Sample Preparation, Assay Development, Biomarker Validation and Testing), End- User (Clinical Diagnostics, Pharmaceutical And Biotechnology Companies, Research Organizations), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa) https://www.databridgemarketresearch.com/reports/global-neurological-biomarkers-market

  • Neurological Monitors Market, By Product Type (Magnetic Resonance Imaging (MRI) Devices, Electroencephalography Devices, Cerebral Oximeters, Intracranial Pressure Monitors, Others), Disease Type (Traumatic Brain Injury (TBI), Stroke, Sleep Disorders, Parkinson's Disease, Epilepsy, Other Diseases), Application (Monitors of Intracranial Pressure and Blood Flow Dynamics, Monitors of Brain Electrical Activity), Procedure (Invasive, Non-Invasive), End User (Healthcare Institutions, Diagnostic Centers and Research Institutes) https://www.databridgemarketresearch.com/reports/global-neurological-monitors-market

  • Lysosomal Storage Disorder Drugs Market, By Treatment (Enzyme Replacement Therapy, Stem Cell Therapy, Substrate Reduction Therapy, Others), Indication (Gaucher's Disease, Fabry Disease, Pompe’s Syndrome, Mucopolysaccharidosis, Others), End User (Hospitals, Clinics and Others) Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) https://www.databridgemarketresearch.com/reports/global-lysosomal-storage-disorder-drugs-market

  • Bipolar Disorder Treatment Market, By Bipolar Disorders Type (Bipolar I and Bipolar II), Drug Class (Anticonvulsants, Antianxiety, Mood Stabilizers, Antipsychotic, Antidepressant and Others), Mechanism of Action (Selective Serotonin Reuptake Inhibitor, Serotonin Norepinephrine Reuptake Inhibitors, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors, Benzodiazepines and Beta Blockers), Route of Administration (Oral, Parenteral and Others), End User (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy and Retail Pharmacy), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) https://www.databridgemarketresearch.com/reports/global-bipolar-disorder-treatment-market

  • Seasonal Affective Disorder Market, By Type (Fall & Winter SAD, Spring & Summer SAD, Others), Physical Exam (Lab Tests, Psychological Evaluation, Others), Treatments (Light Therapy, Medications, Psychotherapy, Counselling, Others), End Use (Hospitals, Clinics, Research Institutes, Others), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of the Middle East & Africa) https://www.databridgemarketresearch.com/reports/global-seasonal-affective-disorder-market

  • Genetic Disorders Market, By Indication (CF, DMD, LSD, PNH), Disease Type (Alzheimer’s Disease, Cancer, Cystic Fibrosis, Sickle Cell Anemia, DMD, Thalassemia, Huntington’s Disease, Rare Diseases, Others), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa) https://www.databridgemarketresearch.com/reports/global-genetic-disorders-market

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact Us:-

Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Email:- corporatesales@databridgemarketresearch.com